N@N

Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack pat

_{//health-fitness.news-articles.net/content/2010/ .. -i-study-of-multistem-r-in-heart-attack-pat.html}
^{Published in Health and Fitness on Wednesday, July 28th 2010 at 13:31 GMT by Market Wire}  

 - Administration of MultiStem was found to be well tolerated at all dose levels - No clinically significant changes in vital signs, allergic reactions, or infusion-related toxicities were associated with MultiStem administration - Each dose group showed improvement in mean left ventricular ejection fraction (LVEF), a measure of heart function, compared to baseline and relative to the registry group - Patients in the 50 million dose group had a statistically significant absolute improvement in mean 4-month LVEF relative to baseline (9.8 percentage points, representing a 23.4% improvement over baseline, p less than 0.02) - Among patients with more severe heart attacks - as measured by baseline LVEFs less than or equal to 45% - the 50 and 100 million dose groups each demonstrated better than a 25% improvement in mean LVEF at 4 months post treatment over baseline 

 Forward Looking Statements --------------------------